Bullish Case: After a 24% ninety-day drawdown to $65.64, the CYTK term structure flipped to contango (Helium ~23% Oct IV vs 47% market IV) and Helium's price density peaks exactly at $65 with meaningful $70–75 mass. Call volume runs 93% above puts, bullish risk outweighs bearish by 31%, and RBC sees CYTK favored in the BMS patent dispute. A stabilizing base with heavy call flow suggests capitulation is largely exhausted.

Bearish Case: CYTK broke hard from $86.49, and Helium's AI forecast correlation is negative (-0.1), so its +2.71% call has historically been unreliable. The put wing (60/65P, 47–53 IV) remains priced, downside density at $55–60 is substantial, and prior bullish ranges ($68–72, $72–79) already missed as price fell through them. Patent risk with BMS, payer/uptake questions, and a 12.7x book multiple leave little cushion.

Potential Outcomes:

1. 40% — Range recovery: $62–72 consolidation into Q4 FDA submission window; Helium/market densities both peak at $65. Falsified by a close below $60 on volume.
2. 25% — Bullish rerate: $72–80 if patent posture strengthens or rollout news lands; 11/20 70C (delta 0.42, heavy volume) is the market's implied vehicle.
3. 25% — Downside continuation: $55–62 if BMS dispute escalates or uptake disappoints; put-IV steepening would confirm.
4. 10% — Tail move (>±25%) from binary regulatory/safety news; deep OTM wings (150% IV) price this.

September 30, 2026